New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
Johnson & Johnson presented new Phase 3 FUZION subgroup data at ACG 2026 showing TREMFYA achieved combined fistula remission in 28% (100 mg q8w) and 27% (200 mg q4w) of Crohn's perianal fistula patients at Week 24 versus 10% on placebo. Prespecified analyses showed consistent benefit across difficult-to-treat subgroups, including prior biologic-exposed patients (21-29% vs 5% placebo), with safety consistent with the known profile.
Key figures
- Drug Name
- TREMFYA (guselkumab)
- Phase Of Trial
- Phase 3
- Placebo remission
- 10%
- Combined fistula remission 100mg q8w
- 28%
- Combined fistula remission 200mg q4w
- 27%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.